3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Completed
1
Sponsor Class
OTHER
98
INDUSTRY
60
NIH
3
NETWORK
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
1
Conditions
Lung Neoplasms
4
Carcinoma, Non-Small-Cell Lung
3
Neoplasm Metastasis
2
Squamous Cell Carcinoma of Head and Neck
1
Small Cell Lung Carcinoma
1
Prostate Cancer Metastatic
1
Oropharyngeal Neoplasms
1
Oligometastatic Squamous Cell Carcinoma of the Head and Neck
1
Neoplasm, Residual
1
Mouth Neoplasms
1
Mesothelioma
1
Melanoma
1
Leukemia, Myeloid, Chronic-Phase
1
Laryngeal Neoplasms
1
Hypopharyngeal Neoplasms
1
Hodgkin Disease
1
Gallbladder Neoplasms
1
Colorectal Neoplasms
1
Clear-cell metastatic renal cell carcinoma
1
Carcinoma, Renal Cell
1
Carcinoma
1
Breast Neoplasms
1
Biliary Tract Neoplasms
1
Anatomic Stage I Breast Cancer AJCC v8
1
Interventions
Cyclophosphamide
39
Docetaxel
30
Tamoxifen
29
Paclitaxel
27
Doxorubicin
26
Trastuzumab
20
Radiotherapy
18
Epirubicin
16
Letrozole
13
exemestane
11
Fluorouracil
11
Anastrozole
11
Capecitabine
10
Bevacizumab
10
Immunohistochemistry
9
Filgrastim
9
Fulvestrant
8
Methotrexate
7
Gene Expression Profiling
7
palbociclib
6
Zoledronic Acid
6
Microarray Analysis
6
Lapatinib
6
Goserelin
6
Chemotherapy, Adjuvant
6
Amplified Fragment Length Polymorphism Analysis
6
Vinorelbine
5
Triptorelin Pamoate
5
Carboplatin
5
Absorptiometry, Photon
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
NETWORK
×
Breast Neoplasms
×
pembrolizumab
×
Clear all
NCT02129556
2019-02-15
PANACEA
ETOP IBCSG Partners Foundation
Phase 1/2
Completed
58 enrolled
16 charts